Trial Profile
A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Boceprevir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naive and PR Prior Treatment Failure Subjects With Chronic HCV GT1 Infection
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Boceprevir; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 14 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 04 Aug 2014 New trial record